Trial Profile

Expanded Access Intermediate Size Treatment Protocol: Pritelivir for Immunocompromised Subjects With Treatment Resistant Herpes Simplex Virus Type 1 or 2

Status: Recruiting

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 19 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

25 Apr 2023 Status changed from planning to recruiting.
14 Feb 2020 New trial record
12 Feb 2020 According to an AiCuris media release, the company and myTomorrows, a Netherlands-based HealthTech company facilitating access to medicines in development and real-world data collection, today announced a collaboration to develop an Early Access Program (EAP) for pritelivir for use in immunocompromised patients that have acyclovir-resistant mucocutaneous herpes simplex virus infections.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com